These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29252508)

  • 1. Abuse-deterrent Opioid Formulations.
    Litman RS; Pagán OH; Cicero TJ
    Anesthesiology; 2018 May; 128(5):1015-1026. PubMed ID: 29252508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.
    Miller CJ; Dart RC; Katz NP; Webster LR
    J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting labels of abuse-deterrent opioid analgesics.
    Webster LR
    J Opioid Manag; 2017; 13(6):415-423. PubMed ID: 29308588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of prodrug technology and its application for developing abuse-deterrent opioids.
    Gudin JA; Nalamachu SR
    Postgrad Med; 2016 Jan; 128(1):97-105. PubMed ID: 26615852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.
    Setnik B; Schoedel KA; Levy-Cooperman N; Shram M; Pixton GC; Roland CL
    J Opioid Manag; 2017; 13(6):485-523. PubMed ID: 29308594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.